Skip to main content

Table 1 Main characteristic of the seven included studies

From: Dexmedetomidine as a promising prevention strategy for cardiac surgery-associated acute kidney injury: a meta-analysis

StudyID

Study type

Number (DEX/Control)

Surgery type

Intervention

Ref (DOI)

DEX

Control

Ammar et al. 2016 [4]

RCT

25/25

Cardiac surgery with CPB

5 min before CPB until 6 h after surgery (1 μg/kg for 15 min and followed by 0.5 μg/kg/h)

Placebo

10.4103/1658-354X.177340

Balkanay et al. 2015 [2]

RCT

60/28

CABG with CPB

After ICU admission and continuing for a maximum of 24 h (0.04 μg/kg/h to 0.5 μg/kg/h)

Placebo

10.1093/icvts/ivu367

Cho et al. 2015 [5]

RCT

100/100

Cardiac surgery with CPB

After anesthetic induction and continuing for 24 h after surgery (0.4 μg/kg/h)

Placebo

10.1038/ki.2015.306

Ji et al. 2013 [3]

Cohort (retrospective)

567/566

CABG/valve surgery with CPB

After CPB and continuing for a maximum of 24 h (0.24 μg/kg/h to 0.6 μg/kg/h)

Control

10.1371/journal.pone.0077446

Kwiatkowski et al. 2016

Cohort (retrospective)

102/102

Cardiac surgery with CPB

NR

Control

10.1097/PCC.0000000000000611

Shehabi et al. 2012

Cohort (prospective)

76/77

Cardiac surgery with CPB

After anesthetic induction and until extubation (0.7 μg/kg/h)

Control

10.1097/01.ccm.0000425199.76669.9f

Turan et al. 2014

Cohort (retrospective)

765/17,011

Cardiac surgery

NR

Control

10.1016/j.jclinane.2014.05.009

  1. CABG coronary artery bypass graft, CPB cardiopulmonary bypass, DEX dexmedetomidine, ICU intensive care unit, NR not reported, RCT randomized controlled trial